30 results on '"Massuti, Bartomeu"'
Search Results
2. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
3. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
4. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
5. BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
6. Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer
7. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
8. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
9. MA06.09 Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin & Chemo-Radiation in Stage III NSCLC. SLCG 10/02
10. MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results
11. P2.03a-045 Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
12. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
13. Association of PALB2Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
14. P2-104: Role of ERCC1, XRCC3, Aurora A and TGFBR1 single nucleotide polymorphisms (SNP) and CHFR and 14-3-3 sigma methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer (NSCLC) patients (p)
15. D4-06: Potential role of molecular markers expression to improve mediastinal nodes staging from resected stage I non-small cell lung cancer (NSCLC)
16. B2-01: The NATCH trial: chemotherapy toxicity and response on the neoadjuvant arm
17. P2-242: First-line treatment with vinorelbine (VRL) plus cisplatin (CDDP) for patients with advanced non-small-cell lung cancer (NSCLC): Molecular correlates
18. P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations
19. P3-130: A large Spanish experience with erlotinib in advanced non–small cell lung cancer
20. P3-114: Erlotinib as first–line treatment for untreated patients with advanced or metastatic non–small cell lung cancer (NSCLC)
21. P3-083: Erlotinib as a single agent in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) and good performance status
22. P3-082: Erlotinib as third and successive line of treatment in advanced or metastatic non-small cell lung cancer patients
23. P3-061: Erlotinib as single agent in elderly patients (p) with advanced or metastatic NSCLC
24. P2-096: Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in blood in advanced non-small cell lung cancer (NSCLC) patients: Analysis of therir prognostic value
25. PD4-2-7: Non-small cell lung cancer in the elderly
26. 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations.
27. Role of ERCC1, XRCC3, Aurora A and TGFBR1 single nucleotide polymorphisms (SNP) and CHFR and 14-3-3 sigma methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer (NSCLC) patients (p).
28. First-line treatment with vinorelbine (VRL) plus cisplatin (CDDP) for patients with advanced non-small-cell lung cancer (NSCLC): Molecular correlates.
29. Potential role of molecular markers expression to improve mediastinal nodes staging from resected stage I non-small cell lung cancer (NSCLC).
30. The NATCH trial: chemotherapy toxicity and response on the neoadjuvant arm.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.